Literature DB >> 22944140

Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia.

Marie Bicikova1, Martin Hill, Daniela Ripova, Pavel Mohr, Richard Hampl.   

Abstract

Metabolomic studies represent a promising tool for early diagnosis of schizophrenia. The aim of this study was to find differences in the steroid spectrum in patients and controls, and to assess the diagnosis of schizophrenia by building a predictive model based on steroid data. Thirty-nine serum steroids (22 neuroactive steroids and their metabolites and 17 polar conjugates) representing steroid metabolome were measured by gas chromatography-mass spectrometry in 22 drug-naive (first episode) schizophrenia patients (13 men and 9 women) before and after six-month treatment with atypical antipsychotics. The results were compared to the data from healthy subjects (22 males, 25 females). In summary the following significant differences were found: (1) In both sexes higher levels of pregnenolone sulfate and sulfated 5α- as well as 5β-saturated metabolites of C21-steroids in progesterone metabolic pathway were found in patients, pointing to decreased activity of sulfatase. (2) In a few instances decreased levels of the respective 5α-metabolites of C21 steroids were found in patients. (3) As C19 steroids concern, in both sexes there were considerably lowered levels of 5β-reduced metabolites in patients. On the other hand, with only a few exceptions, the treatment did not significantly influence most steroid levels. Further, to assess the relationships between schizophrenia status and steroid levels and to build the predictive model of schizophrenia, multivariate regression with reduction of dimensionality (the method of orthogonal projections to latent structures, OPLS) was applied. Irrespective of the small number of patients, use of this model enabled us to state the diagnosis of schizophrenia with almost 100% sensitivity. Our findings suggest that the assessment of steroid levels may become a valid and accurate laboratory test in psychiatry. A limitation of our study is the absence of subjects with a diagnosis other than schizophrenia, so we cannot conclude whether the results are specific for schizophrenia. On the other hand, steroid metabolome model may be used as a diagnostic tool for further studies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22944140     DOI: 10.1016/j.jsbmb.2012.08.009

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  20 in total

1.  Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Authors:  Roberto Frau; Federico Abbiati; Valentina Bini; Alberto Casti; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Schizophr Res       Date:  2015-05-18       Impact factor: 4.939

Review 2.  Effects of Sex Steroids in the Human Brain.

Authors:  Tuong-Vi Nguyen; Simon Ducharme; Sherif Karama
Journal:  Mol Neurobiol       Date:  2016-11-08       Impact factor: 5.590

3.  Medroxyprogesterone acetate is associated with increased sleep spindles during non-rapid eye movement sleep in women referred for polysomnography.

Authors:  David T Plante; Michael R Goldstein
Journal:  Psychoneuroendocrinology       Date:  2013-09-06       Impact factor: 4.905

4.  Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia.

Authors:  Khaled Al Awam; Ida Sibylle Haußleiter; Ed Dudley; Rossen Donev; Martin Brüne; Georg Juckel; Johannes Thome
Journal:  J Neural Transm (Vienna)       Date:  2014-05-01       Impact factor: 3.575

Review 5.  Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?

Authors:  Andrea Gogos; Luke J Ney; Natasha Seymour; Tamsyn E Van Rheenen; Kim L Felmingham
Journal:  Br J Pharmacol       Date:  2019-03-14       Impact factor: 8.739

6.  Inhibition of CaV3.2 T-type calcium channels in peripheral sensory neurons contributes to analgesic properties of epipregnanolone.

Authors:  Christine Ayoola; Sung Mi Hwang; Sung Jun Hong; Kirstin E Rose; Christopher Boyd; Neda Bozic; Ji-Yong Park; Hari Prasad Osuru; Michael R DiGruccio; Douglas F Covey; Vesna Jevtovic-Todorovic; Slobodan M Todorovic
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

Review 7.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

Review 8.  Role of cholesterol sulfate in epidermal structure and function: lessons from X-linked ichthyosis.

Authors:  Peter M Elias; Mary L Williams; Eung-Ho Choi; Kenneth R Feingold
Journal:  Biochim Biophys Acta       Date:  2013-11-27

Review 9.  Pregnenolone sulfate as a modulator of synaptic plasticity.

Authors:  Conor C Smith; Terrell T Gibbs; David H Farb
Journal:  Psychopharmacology (Berl)       Date:  2014-07-06       Impact factor: 4.530

10.  Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Authors:  Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.